Category Archives: Health Professionals

MD and CEO of InnovaCare Health Leadership, Richard Shinto

Dr. Richard Shinto holds the current CEO and president at InnovaCare Inc. He has served as the CEO and president of Avnet Inc. From 2008 to 2012 when the company was sold. Before then he had been in the company’s managerial team. His service as the CEO of InnovaCare continues as he has plans over in Puerto Rico.

Shinto is well known and celebrated for the more than two decades experience he has in operational and clinical healthcare management. Before becoming the CEO of Avete, he was the active Chief medical officer at NAMM California. Long before that, he had held a position of the chief operating officer at the Medical Pathways Management Company. He has also been the corporate Vice president of Med Partners’ medical management from 1996 to 1997 from where he left to become the Chief Medical Officer for Cal Optima Health Plan in the Orange County of California. Learn more about Rick on XRepublic.

Dr. Shinto’s career started off with internist and pulmonologist responsibilities when practicing in Southern California. He has authored a number of articles in health care as well as clinical medicine. He got his Bachelor’s from the University of California, Irvine and his medical degree at the State University of New York over at Stony Brook. He also holds a University of Redlands master’s degree in the same. These academic qualifications combined with experience of more than twenty years makes Dr. Richard Shinto a force to reckon with in the industry.

From the time Richard Shinto joined the other three professionals at InnovaCare, he has proven to be a useful resource ever since. He is attributed to be the force behind the change happening at InnovaCare Health with everyone acknowledging that it is part for his efforts that makes the company enjoy its current success. Rick Shinto believes that the company will make major strides in expansion to other markets, which will in turn contribute towards its growth, and patients help.

InnovaCare makes its easy, convenient and affordable to visit the doctor’s office. More residents of Puerto Rica have better and easy access to good medical care. This package by the Innovacare leadership has attracted a huge following. The company uses technology wisely which makes it easy and possible to get cheaper medical options at affordable prices. This explains how the leadership has been able to achieve a following of more than 70 percent new signups. Read this article at

Accomplishing Milestones in Business, A Profile on JeanMarie Guenot


JeanMarie Guenot holds a Ph. D and has over two decades of experience within biotechnology and the pharmaceutical industry. She has specific expertise in the building and rebuilding companies, in addition to working in both the public and private sector. JeanMarie is both the President and CEO of Amphivena Therapeutics, Incorporated. Amphivena focuses on development of antibody therapies that treat hematologic malignancies. Before she became President and CEO of Amphivena, Dr. JeanMarie Guenot developed and ran SKS Ocular. While at SKS Ocular, she developed technologies and therapeutics for glaucoma, ocular inflammation, and other eye-related health issues. All of which is available on her Facebook page:


In addition to being a success in the field of biotechnology, Dr. Guenot has managed venture capital investments at Atlas Venture. A fine business leader with a keen sense for the aggressive development of needed biotechnology treatments, JeanMarie Guenot also has a solid foundation as a scientist. She led an 800 million dollar transaction, involving Biogen Idec-PDL 50:50, which she co-developed and co-commercialized. During her collegiate studies, she focused on Chemistry, with an emphasis on protein structure prediction, drug design, and methods for molecular dynamics. She developed drugs for autoimmune diseases, and inflammation while working at Preclinical R&D at Hoffmann-La Roche. Her Guenot LLC bio shows Jeanmarie earned a Ph.D. from the University of California, San Francisco and an MBA from The Wharton School at the University of Pennsylvania.


Amphivena Therapeutics Incorporated, based in San Francisco, California, is a developer of immunotherapies for cancer. The company’s leading drug treatments focus on acute myeloid leukemia, also known as AML. Constantly making advances in medicine, in August 2016, the FDA accepted an investigational new drug application from Amphivena, known as AMV564. A clinical study focused on AMV564 will research the safety of, in addition to the necessary doses for treating patients with AML. Apmhivena and its progress in biotechnology and pharmaceutical developments have been reported by outlets, such as MarketWired and Yahoo! Finance.